ReviewFrontiers in bioengineering and biotechnology2025
Pioneering biomimetic biomaterial for leukemia therapy enhancement: a review.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leukemia is a highly recurrent and metastatic hematologic malignancy. The disease poses significant challenges to conventional therapies due to drug resistance, systemic toxicity, and poor drug targeting efficiency. Biomimetic biomaterials offer unique advantages for precision leukemia therapy, surpassing conventional synthetic materials in biocompatibility, biodegradability, immune evasion, and inherent targeting. These properties enable applications such as hydrogel-encapsulated systems for NK cell culture and platelet-mimetic nanocarriers for targeted drug delivery. This review first elucidates the characteristics of leukemia from microenvironmental, metabolic, and immunoregulatory perspectives. It then summarizes the design principles of biomimetic biomaterials tailored for leukemia therapy. Furthermore, the article details diverse applications of these strategies in anti-leukemic biomaterial platforms. Finally, the challenges and future opportunities for biomimetic anti-leukemia biomaterials are critically discussed across translational, technological, and interdisciplinary dimensions. By providing a comprehensive reference for researchers, this review aims to inspire innovative strategies and accelerate the development of next-generation biomaterials for leukemia treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.